BIOMAT Database Logo BIOMAT Database Logo

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity. 2023

Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.

SMARCA2 is an attractive synthetic lethality target for human cancers with SMARCA4 deficiency. Herein, we report the design, synthesis, and biological evaluation of selective SMARCA2 protein degraders developed using the proteolysis targeting chimera (PROTAC) technology. Our efforts have led to the discovery of a series of potent and selective SMARCA2 degraders, exemplified by SMD-3040. SMD-3040 degrades SMARCA2 protein with a low nanomolar DC50 and Dmax > 90% and demonstrates an excellent degradation selectivity for SMARCA2 protein over SMARCA4 protein. It displays potent cell growth inhibitory activity in a panel of SMARCA4-deficient cancer cell lines and has much weaker activity in SMARCA4 wild-type cancer cell lines. SMD-3040 achieves strong tumor growth inhibition in two SMARCA4-deficient xenograft models at well-tolerated dose schedules. Further optimization of SMD-3040 may lead to the discovery of new therapies for the treatment of human cancers with SMARCA4 deficiency.

UI MeSH Term Description Entries
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D004265 DNA Helicases Proteins that catalyze the unwinding of duplex DNA during replication by binding cooperatively to single-stranded regions of DNA or to short regions of duplex DNA that are undergoing transient opening. In addition, DNA helicases are DNA-dependent ATPases that harness the free energy of ATP hydrolysis to translocate DNA strands. ATP-Dependent DNA Helicase,DNA Helicase,DNA Unwinding Protein,DNA Unwinding Proteins,ATP-Dependent DNA Helicases,DNA Helicase A,DNA Helicase E,DNA Helicase II,DNA Helicase III,ATP Dependent DNA Helicase,ATP Dependent DNA Helicases,DNA Helicase, ATP-Dependent,DNA Helicases, ATP-Dependent,Helicase, ATP-Dependent DNA,Helicase, DNA,Helicases, ATP-Dependent DNA,Helicases, DNA,Protein, DNA Unwinding,Unwinding Protein, DNA,Unwinding Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072020 Synthetic Lethal Mutations Mutations in genes which lead to cell or organism death when occurring in combination with mutations in one or more other genes. Synthetic Lethal Mutation,Synthetic Lethality,Lethal Mutation, Synthetic,Lethal Mutations, Synthetic,Lethality, Synthetic,Mutation, Synthetic Lethal,Mutations, Synthetic Lethal
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses

Related Publications

Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.
February 2023, Journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.
September 2023, Journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.
April 2024, Journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
January 2024, European journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
December 2019, Nature medicine,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
April 2024, Bioorganic & medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
June 2024, Bioorganic & medicinal chemistry letters,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
August 2022, Journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
December 2019, Journal of medicinal chemistry,
Lin Yang, and Wenbin Tu, and Liyue Huang, and Bukeyan Miao, and Atsunori Kaneshige, and Wei Jiang, and Lingying Leng, and Meilin Wang, and Bo Wen, and Duxin Sun, and Shaomeng Wang
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activity.
April 2024, Molecular cancer therapeutics,
Copied contents to your clipboard!